Keyphrases
Type 2 Diabetic Patients
100%
Exenatide Once Weekly
100%
Type 2 Diabetes Mellitus (T2DM)
60%
Liraglutide
60%
Type 2 Diabetes Prevention
60%
Semaglutide
60%
Glucagon-like peptide-1 Receptor (GLP-1R)
40%
Formulation Method
20%
Diabetes
20%
Novel Formulations
20%
Glucagon-like
20%
Overall Risk
20%
Safe Treatment
20%
Head-to-head Trials
20%
Receptor Agonist
20%
A1 Receptor
20%
Expert Opinion
20%
Consensus Document
20%
Future Management
20%
Exenatide
20%
Cardiovascular Risk Reduction
20%
Fasting Plasma Glucose
20%
Europe
20%
Novel Delivery
20%
Risk-benefit
20%
Mode of Delivery
20%
Area Cover
20%
Glycated Hemoglobin A1c
20%
European Associations
20%
American Diabetes Association
20%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Exendin 4
100%
Liraglutide
37%
Semaglutide
37%
Novel Formulation
12%
Hemoglobin A1c
12%
Cardiovascular Risk
12%
Glucagon Like Peptide 1 Receptor Agonist
12%